Brooks Nader Says ‘So Many Women’ Have Reached Out About GLP-1 Addiction
Brooks Nader was surprised to see an outpouring of support from women from all walks of life after she opened up about her addiction to weight loss drugs. “I didn’t quite know how many other women are going through the same thing that I was going though,” Nader, 28, told Us Weekly exclusively at iHeartRadio’s […]
Risk for Epilepsy Reduced With GLP-1 Receptor Agonist Use in Type 2 Diabetes
MONDAY, Dec. 15, 2025 — For adults with type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy is associated with a reduced risk for epilepsy, according to a study published online Dec. 10 in…
2 Predictions for Eli Lilly in 2026
Key Points Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly’s shares look attractive even at current levels. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) recently […]
Lawsuits alleging GLP-1 drugs led to blindness to be centralized
Post Content
Noom Pivots to Longevity: New Program Combines Microdose GLP-1s with At-Home Biomarker Testing
What You Should Know: – Noom has launched Proactive Health Microdose GLP-1Rx, a first-of-its-kind preventive health program designed to intervene before chronic disease takes root. – Available to individuals with a BMI of 21 or higher, the offering combines personalized microdoses of GLP-1 medication with comprehensive at-home biomarker testing and Noom’s digital behavior modification platform. […]
指控Ozempic及其他GLP-1类药物导致失明的诉讼案，成为针对该类药物的第二起集体诉讼。
Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs (www.reuters.com) 04:21
PHTI Report 2025: 5 Strategies for Employers to Manage GLP-1 Costs and Coverage
What You Should Know: – The Peterson Health Technology Institute (PHTI) has released a critical purchasing guide for employers struggling to manage the skyrocketing costs of GLP-1 obesity medications. – The report recommends a shift away from broad, unchecked coverage toward a managed approach focused on three phases: Initiation (strict eligibility), Maintenance (adherence support), and […]
With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels
The telehealth company Noom plans to target people with a body mass index well below the requirements for FDA-approved obesity shots, using a microdose GLP-1 offering. The strategy is becoming more common, as online health …
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the EU approval of a higher dose of its blockbuster obesity injection, Wegovy (semaglutide). NVO expects a final decision from the European Commission early in 2026. The regulatory filing in the EU seeks […]
GLP-1 medications may Lower Epilepsy Risk in individuals with type 2 diabetes, according to a recent study. Drugs that mimic the action of the hormone glucagon-like peptide-1 (GLP-1) include semaglutide.
submitted by /u/ranjitsingh7 [link] [comments]